Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883791 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL18458206 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21582882 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL14984949 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL6883789 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL23710407 | 0.94 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL7459014 | 0.93 | METAP2 (0.77) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL13799963 | 0.93 | METAP2 (0.77) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL18458208 | 0.91 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL19880170 | 0.91 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158046-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | Mersana Therapeutics, Inc (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158046-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | Mersana Therapeutics, Inc (US) | 2013-06-20 | — | — | US | disclosed |
| US-8399512-B2 | Biocompatible biodegradable fumagillin analog conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399512-B2 | Biocompatible biodegradable fumagillin analog conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20090148396-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090148396-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148396-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | VEGFA, FLT1, FLT4 | METAP2 3236/4885ABCB11 2639/4885LMNA 2995/4885 |
| US-20130158046-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | VEGFA, FLT1, FLT4 | METAP2 3236/4885ABCB11 2639/4885LMNA 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.